Clinical trial
Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer
NCT00004236 · University of Leicester, Other · Unknown status
Key facts
| NCT number | NCT00004236 |
|---|---|
| Title | Liposomal Doxorubicin in Treating Patients With Advanced Stomach Cancer |
| Official title | A Phase II Study of Caelyx in the Treatment of Advanced Gastric Cancer |
| Lead sponsor | University of Leicester, Other |
| Status | Unknown status |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Esophageal Cancer, Gastric Cancer |
| Intervention type | Drug |
| Interventions | pegylated liposomal doxorubicin hydrochloride |
| Start date | Aug 1, 1998 |
| First posted | Jun 9, 2004 |
| Last update posted | Jun 24, 2014 |
| Countries | United Kingdom |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: